Holen Sie sich die Stockscreener-App
19.40
2.16%
0.41
Schlusskurs vom Vortag:
$18.99
Offen:
$19.16
24-Stunden-Volumen:
1.52M
Relative Volume:
0.86
Marktkapitalisierung:
$2.20B
Einnahmen:
$70.92M
Nettoeinkommen (Verlust:
$-342.21M
KGV:
-5.1535
EPS:
-3.7644
Netto-Cashflow:
$-304.30M
1W Leistung:
-5.23%
1M Leistung:
-14.84%
6M Leistung:
+2.97%
1J Leistung:
-8.58%
1-Tages-Spanne:
$18.92
$19.55
1-Wochen-Bereich:
$18.92
$20.85
52-Wochen-Spanne:
$13.18
$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Firmenname
Viridian Therapeutics Inc
Sektor
Branche
Telefon
617.272.4600
Adresse
221 CRESCENT STREET, WALTHAM
Compare VRDN vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
19.40 | 2.32B | 70.92M | -342.21M | -304.30M | -3.7644 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Bestätigt | Wedbush | Outperform |
| 2025-12-03 | Eingeleitet | William Blair | Outperform |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-08-25 | Fortgesetzt | Jefferies | Buy |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Eingeleitet | TD Cowen | Buy |
| 2024-09-11 | Bestätigt | Needham | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-05-09 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Eingeleitet | BTIG Research | Buy |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-05-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-04-17 | Eingeleitet | Wells Fargo | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2022-12-19 | Eingeleitet | Cowen | Outperform |
| 2022-12-19 | Eingeleitet | Needham | Buy |
| 2022-12-16 | Eingeleitet | Credit Suisse | Outperform |
| 2022-12-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-23 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-18 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-12 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
Viridian Therapeutics stock weighs Lumvoa uptake against losses - AD HOC NEWS
ETFs Investing in Viridian Therapeutics, Inc. Stocks - TradingView
Discontinued operations of Viridian Therapeutics, Inc. – HAN:1S1 - TradingView
1S1 Forecast — Price Target — Prediction for 2027 - TradingView
(VRDN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says - Yahoo Finance
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $38 - Moomoo
RBC Capital maintains Outperform rating on Viridian Therapeutics, $38 price target - TradingView
VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval - Stocktwits
Viridian Therapeutics shifts focus to launch ex... - Pluang
Viridian Therapeutics: Two Products, One Commercial Buildout (NASDAQ:VRDN) - Seeking Alpha
Sling Therapeutics raises $123 million to advance thyroid eye disease drug - reuters.com
Viridian at Wells Fargo conference: launch gains and pipeline build By Investing.com - Investing.com Canada
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying - Benzinga
Wells Fargo Keeps Their Buy Rating on Kyverna Therapeutics, Inc. (KYTX) - theglobeandmail.com
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference - Yahoo Finance
Viridian Therapeutics Inc (VRDN:UW): Stock Price, Quote and News - BNN Bloomberg
260,000 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Blue Owl Capital Holdings LP - MarketBeat
Deep Track Capital, LP Trims Viridian Therapeutics (VRDN) Stake in Strategic Rebalancing - GuruFocus
Viridian Therapeutics CLO Jennifer Tousignant sells $348,194 in shares By Investing.com - Investing.com Canada
Viridian Therapeutics CLO Jennifer Tousignant sells $348,194 in shares - Investing.com
Viridian Therapeutics (NASDAQ:VRDN) Insider Jennifer Tousignant Sells 14,212 Shares - MarketBeat
Viridian Therapeutics (VRDN) legal chief sells 14,212 shares - Stock Titan
Viridian (VRDN) Latest Quarter: Reported Results Sit Close to Expectations; Session Move: The Stock Ends Down 1.21% in Latest TradingEarnings Preview - Vinanet
Steven Cohen’s Point72 discloses Viridian stake (VRDN) - Stock Titan
Viridian Therapeutics (VRDN) Could Be 83% Undervalued On Fresh Earnings Numbers - Sahm
Handelsbanken Fonder AB Invests $834,000 in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Goldman Sachs Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Viridian (NASDAQ: VRDN) insider to sell 14,212 shares in August 2026 - Stock Titan
GSA Capital Partners LLP Invests $903,000 in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian (NASDAQ: VRDN) CMO acquires 40K shares via option - Stock Titan
93,414 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Merck & Co. Inc. - MarketBeat
1,175,906 Shares in Viridian Therapeutics, Inc. $VRDN Bought by Rice Hall James & Associates LLC - MarketBeat
Bank of America Corp DE Acquires 173,498 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Viridian Therapeutics Stock Price Forecast. Should You Buy VRDN? - StockInvest.us
Paradigm BioCapital reports 6.1% Viridian (VRDN) stake and 5.3% held by offshore fund - Stock Titan
Kynam Capital group (VRDN) discloses shared power over 6.45M Viridian shares - Stock Titan
T. Rowe Price Associates (VRDN) discloses 5.2% Viridian Therapeutics ownership in 13G - Stock Titan
Deep Track group reports 3.25% Viridian Therapeutics (VRDN) ownership in latest filing - Stock Titan
Viridian Therapeutics, Inc. (1S1) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Trading the Move, Not the Narrative: (VRDN) Edition - news.stocktradersdaily.com
Viridian Therapeutics, Inc. Stock 12‑Month Price Target Cut to $36.07, Implies 58% Upside - TradingView
Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $39 - Moomoo
Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 22% - simplywall.st
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Viridian Therapeutics (VRDN) Rises 2.84% as Biotech Stock Approaches Key Resistance at $24.9Volatility Smile - careplusvn.com
Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $26 - Moomoo
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported And Analysts Have Been Cutting Their Estimates - 富途牛牛
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Renaissance Technologies LLC Takes $3.97 Million Position in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Finanzdaten der Viridian Therapeutics Inc-Aktie (VRDN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Viridian Therapeutics Inc-Aktie (VRDN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tousignant Jennifer | Chief Legal Officer |
Aug 19 '26 |
Sale |
24.50 |
14,212 |
348,194 |
0 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):